Diabetes Mellitus, Non-Insulin-Dependent
Lilly’s oral GLP-1 succeeds in first Phase III test, delivering promising weight loss
orforglipron, Glucagon-Like Peptide 1, Weight Loss, Oral cavity, orforglipron, Phase 3 Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Hemoglobin A1c measurement, Safety, Injectables
Dexcom survey shows healthcare providers opt for CGM tech over new medications in Type 2 diabetes
Continuous Glucose Monitoring System, Technology, Health Personnel, CGM, Diabetes Mellitus, Non-Insulin-Dependent
GLP-1 Medications: Balancing Efficacy and Concerns Amidst Celebrity Endorsements and Rising Demand
GLP-1 agonists, Weight loss, Type 2 diabetes, Celebrity endorsements, Side effects, Long-term safety, Cost implications, Employer health plans
FDA Approves First Generic Version of Victoza (Liraglutide) for Type 2 Diabetes Treatment
FDA approval, generic Victoza, liraglutide, GLP-1 receptor agonist, Type 2 diabetes treatment, affordable medication options
Novo Nordisk’s Vision for the Future of GLP-1 Therapies: Expanding Beyond Diabetes and Obesity
GLP-1 agonists, Novo Nordisk, Type 2 diabetes, Obesity, Future treatments, Chronic diseases, Semaglutide, Tirzepatide, Therapeutic advancements
FDA Reconsiders Removal of Eli Lilly’s Tirzepatide from Shortage List, Boosting Compounding Pharmacies
FDA, Eli Lilly, Tirzepatide, GLP-1 drug, Shortage list, Compounding pharmacies, Weight loss medication, Type 2 diabetes treatment
Lilly’s Weekly Insulin Candidate Efsitora Alfa Shows Promising Results in Phase III Trials
Eli Lilly, Efsitora Alfa, Weekly Insulin, Type 1 Diabetes, Type 2 Diabetes, Phase III Trials, QWINT Studies, Diabetes Treatment
EASD24: Lilly’s Weekly Insulin Efsitora Demonstrates Efficacy but Raises Hypoglycemia Concerns
Eli Lilly, EASD24, Weekly Insulin, Efsitora, Type 1 Diabetes, Type 2 Diabetes, Hypoglycemia, Insulin Therapy
FDA Rejects Novo Nordisk’s Once-Weekly Insulin Icodec for Diabetes Treatment
FDA, Novo Nordisk, Icodec, Weekly Insulin, Diabetes Treatment, Type 1 Diabetes, Type 2 Diabetes, Complete Response Letter
Novo Nordisk’s Ozempic Shows Promising Kidney Benefits for Diabetic Patients
Ozempic, Novo Nordisk, Chronic kidney disease, Cardiovascular events, Expanded use, Semaglutide, FLOW trial, Reduced risk, Type 2 diabetes